Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AffOrg.i » - entrée « Université de Kyoto »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Université de Jilin < Université de Kyoto < Université de Kyūshū  Facettes :

List of bibliographic references indexed by Université de Kyoto

Number of relevant bibliographic references: 35.
[0-20] [0 - 20][0 - 35][20-34][20-40]
Ident.Authors (with country if any)Title
000156 (2020) Shuichiro Nakabo [Japon] ; Yuko Tsuji [Japon] ; Maiko Inagaki [Japon] ; Hideaki Tsuji [Japon] ; Toshiki Nakajima [Japon] ; Kosaku Murakami [Japon] ; Chikashi Terao [Japon] ; Motomu Hashimoto [Japon] ; Moritoshi Furu [Japon] ; Masao Tanaka [Japon] ; Hiromu Ito [Japon] ; Takao Fujii [Japon] ; Tsuneyo Mimori [Japon] ; Yasutomo Fujii [Japon]Severe joint deformity and Patient Global Assessment of Disease are associated with discrepancies between sonographic and clinical remission: A cross-sectional study of rheumatoid arthritis patients.
000190 (2020) Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]Response to: 'Some concerns from Turkey' by Bilgin et al.
000335 (2020) Hiroto Minamino [Japon] ; Masao Katsushima [Japon] ; Tamami Yoshida [Japon] ; Motomu Hashimoto [Japon] ; Yoshihito Fujita [Japon] ; Mirei Shirakashi [Japon] ; Wataru Yamamoto [Japon] ; Kosaku Murakami [Japon] ; Koichi Murata [Japon] ; Kohei Nishitani [Japon] ; Masao Tanaka [Japon] ; Hiromu Ito [Japon] ; Nobuya Inagaki [Japon] ; Shuichi Matsuda [Japon]Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
000432 (2020) Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon]Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
000905 (2019) Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee.
000A57 (2019) Noriko Iwamoto [Japon] ; Megumi Takanashi [Japon] ; Kotoko Yokoyama [Japon] ; Atsushi Yonezawa [Japon] ; Masaya Denda [Japon] ; Motomu Hashimoto [Japon] ; Masao Tanaka [Japon] ; Hiromu Ito [Japon] ; Minoru Matsuura [Japon] ; Shuji Yamamoto [Japon] ; Yusuke Honzawa [Japon] ; Kazuo Matsubara [Japon] ; Takashi Shimada [Japon]Multiplexed monitoring of therapeutic antibodies for inflammatory diseases using Fab-selective proteolysis nSMOL coupled with LC-MS.
000D54 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
000D55 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
000F98 (2019) Noriko Iwamoto [États-Unis] ; Atsushi Yonezawa [Japon] ; Kazuo Matsubara [Japon] ; Takashi Shimada [États-Unis]Acceleration of nano-surface and molecular-orientation limited (nSMOL) proteolysis with acidified reduction pretreatment for quantification of Tocilizumab.
001129 (2018) Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonoti Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon]Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
001361 (2018) Tatiana A. Karakasheva [États-Unis] ; Eric W. Lin [États-Unis] ; Qiaosi Tang [États-Unis] ; Edmund Qiao [États-Unis] ; Todd J. Waldron [États-Unis] ; Monica Soni [États-Unis] ; Andres J. Klein-Szanto [États-Unis] ; Varun Sahu [États-Unis] ; Devraj Basu [États-Unis] ; Shinya Ohashi [Japon] ; Kiichiro Baba [Japon] ; Zachary T. Giaccone [États-Unis] ; Sarah R. Walker [États-Unis] ; David A. Frank [États-Unis] ; E Paul Wileyto [États-Unis] ; Qi Long [États-Unis] ; Margaret C. Dunagin [États-Unis] ; Arjun Raj [États-Unis] ; J Alan Diehl [États-Unis] ; K K Wong [États-Unis] ; Adam J. Bass [États-Unis] ; Anil K. Rustgi [États-Unis]IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.
001379 (2018) Motomu Hashimoto [Japon] ; Moritoshi Furu [Japon] ; Wararu Yamamoto [Japon] ; Takanori Fujimura [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Ohnishi [Japon] ; Kengo Akashi [Japon] ; Shuzo Yoshida [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Toru Hirano [Japon] ; Kosuke Ebina [Japon] ; Ryuji Uozumi [Japon] ; Hiromu Ito [Japon] ; Masao Tanaka [Japon] ; Koichiro Ohmura [Japon] ; Takao Fujii [Japon] ; Tsuneyo Mimori [Japon]Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
001414 (2018) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Akira Ohnishi [Japon] ; Daijiro Kabata [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Shuzo Yoshida [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Kengo Akashi [Japon] ; Takanori Fujimura [Japon] ; Makoto Hirao [Japon] ; Keiichi Yamamoto [Japon] ; Ayumi Shintani [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
001876 (2017) Shuichiro Nakabo ; Motomu Hashimoto ; Shinji Ito ; Moritoshi Furu [Japon] ; Hiromu Ito [Japon] ; Takao Fujii ; Hajime Yoshifuji ; Yoshitaka Imura ; Ran Nakashima ; Kosaku Murakami ; Nobuo Kuramoto ; Masao Tanaka ; Junko Satoh ; Akihito Ishigami [Japon] ; Satoshi Morita [Japon] ; Tsuneyo Mimori ; Koichiro OhmuraCarbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies
001974 (2016) Naonobu Sugiyama [Japon] ; Yutaka Kawahito [Japon] ; Takao Fujii [Japon] ; Tatsuya Atsumi [Japon] ; Tatsunori Murata [Japon] ; Yosuke Morishima [Japon] ; Yuri Fukuma [Japon]Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
001A11 (2016) Takayoshi Morita [Japon] ; Yoshihito Shima [Japon] ; James Badger Wing [Japon] ; Shimon Sakaguchi [Japon] ; Atsushi Ogata [Japon] ; Atsushi Kumanogoh [Japon]The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis
001A82 (2016) Yasufumi Masaki [Japon] ; Hiroshi Kawabata [Japon] ; Kazue Takai [Japon] ; Masaru Kojima [Japon] ; Norifumi Tsukamoto [Japon] ; Yasuhito Ishigaki [Japon] ; Nozomu Kurose [Japon] ; Makoto Ide [Japon] ; Jun Murakami [Japon] ; Kenji Nara [Japon] ; Hiroshi Yamamoto [Japon] ; Yoko Ozawa [Japon] ; Hidekazu Takahashi [Japon] ; Katsuhiro Miura [Japon] ; Tsutomu Miyauchi [Japon] ; Shinichirou Yoshida [Japon] ; Akihito Momoi [Japon] ; Nobuyasu Awano [Japon] ; Soichiro Ikushima [Japon] ; Yasunori Ohta [Japon] ; Natsue Furuta [Japon] ; Shino Fujimoto [Japon] ; Haruka Kawanami [Japon] ; Tomoyuki Sakai [Japon] ; Takafumi Kawanami [Japon] ; Yoshimasa Fujita [Japon] ; Toshihiro Fukushima [Japon] ; Shigeo Nakamura [Japon] ; Tomohiro Kinoshita [Japon] ; Sadao Aoki [Japon]Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.
001E94 (2015) Atsushi Ogata [Japon] ; Tatsuya Atsumi [Japon] ; Takaaki Fukuda [Japon] ; Yasuhiko Hirabayashi [Japon] ; Masaaki Inaba [Japon] ; Naoki Ishiguro [Japon] ; Motokazu Kai [Japon] ; Daisuke Kawabata [Japon] ; Daihei Kida [Japon] ; Hitoshi Kohsaka [Japon] ; Ryutaro Matsumura [Japon] ; Seiji Minota [Japon] ; Masaya Mukai [Japon] ; Takayuki Sumida [Japon] ; Kiyoshi Takasugi [Japon] ; Shigenori Tamaki [Japon] ; Tsutomu Takeuchi [Japon] ; Atsuhisa Ueda [Japon] ; Kazuhiko Yamamoto [Japon] ; Hisashi Yamanaka [Japon] ; Hajime Yoshifuji [Japon] ; Akira Nomura [Japon]Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis.
002014 (2015) Ryoko Sakai [Japon] ; Soo-Kyung Cho [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Michi Tanaka [Japon] ; Ryuji Koike [Japon] ; Yoshiya Tanaka [Japon] ; Kazuyoshi Saito [Japon] ; Shintaro Hirata [Japon] ; Koichi Amano [Japon] ; Hayato Nagasawa [Japon] ; Takayuki Sumida [Japon] ; Taichi Hayashi [Japon] ; Takahiko Sugihara [Japon] ; Hiroaki Dobashi [Japon] ; Shinsuke Yasuda [Japon] ; Tetsuji Sawada [Japon] ; Kazuhiko Ezawa [Japon] ; Atsuhisa Ueda [Japon] ; Takao Fujii [Japon] ; Kiyoshi Migita [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon]Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
002417 (2014) Motomu Hashimoto [Japon] ; Takao Fujii [Japon] ; Masahide Hamaguchi [Japon] ; Moritoshi Furu [Japon] ; Hiromu Ito [Japon] ; Chikashi Terao [Japon] ; Keiichi Yamamoto [Japon] ; Wataru Yamamoto [Japon] ; Takashi Matsuo [Japon] ; Masato Mori [Japon] ; Koichiro Ohmura [Japon] ; Hiroshi Kawabata [Japon] ; Tsuneyo Mimori [Japon]Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis.
002514 (2014) Hisashi Urushihara [Japon] ; Koji Kawakami [Japon]Academic Clinical Trials and Drug Regulations in Japan: Impacts of Introducing the Investigational New Drug System.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AffOrg.i -k "Université de Kyoto" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AffOrg.i  \
                -Sk "Université de Kyoto" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AffOrg.i
   |clé=    Université de Kyoto
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021